dacarbazine and nms-p118

dacarbazine has been researched along with nms-p118 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Borghi, D; Busel, AA; Caprera, F; Casale, E; Ciomei, M; Cirla, A; Corti, E; D'Anello, M; Donati, D; Fasolini, M; Felder, ER; Forte, B; Galvani, A; Isacchi, A; Khvat, A; Krasavin, MY; Lupi, R; Montagnoli, A; Orsini, P; Papeo, G; Perego, R; Pesenti, E; Pezzetta, D; Posteri, H; Rainoldi, S; Riccardi-Sirtori, F; Scolaro, A; Sola, F; Zuccotto, F1

Other Studies

1 other study(ies) available for dacarbazine and nms-p118

ArticleYear
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
    Journal of medicinal chemistry, 2015, Sep-10, Volume: 58, Issue:17

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Female; Heterografts; High-Throughput Screening Assays; Humans; Isoindoles; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Models, Molecular; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Temozolomide; Triple Negative Breast Neoplasms

2015